Alane P Barnes insider trades: Biocryst Pharmaceuticals (BCRX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Alane reports to the SEC
Open-market buys and sales
15 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 13, 2026 | BCRX | ↓ Sell10b5-1 | 62,500 | $9.54 | $596K | Direct | May 15, 2026 (2d) |
| Mar 16, 2026 | BCRX | ↓ Sell10b5-1 | 150,000 | $9.15 | $1.4M | Direct | Mar 18, 2026 (2d) |
| Dec 22, 2025 | BCRX | ↓ Sell10b5-1 | 21,773 | $7.65 | $167K | Direct | Dec 23, 2025 (1d) |
| Dec 15, 2025 | BCRX | ↓ Sell10b5-1 | 21,210 | $7.65 | $162K | Direct | Dec 16, 2025 (1d) |
| Dec 3, 2025 | BCRX | ↓ Sell10b5-1 | 161,680 | $7.21 | $1.2M | Direct | Dec 3, 2025 (0d) |
| May 13, 2024 | BCRX | ↑ Buy | 5,000 | $5.53 | $28K | Direct | May 15, 2024 (2d) |
| Dec 15, 2022 | BCRX | ↓ Sell | 4,175 | $10.88 | $45K | Direct | Dec 19, 2022 (4d) |
| May 11, 2021 | BCRX | ↓ Sell | 102,780 | $12.04 | $1.2M | Direct | May 13, 2021 (2d) |
| Dec 11, 2020 | BCRX | ↓ Sell | 13,741 | $7.96 | $109K | Direct | Dec 15, 2020 (4d) |
| Dec 4, 2020 | BCRX | ↓ Sell | 13,741 | $6.23 | $86K | Direct | Dec 8, 2020 (4d) |
| Nov 18, 2019 | BCRX | ↑ Buy | 20,000 | $1.45 | $29K | Direct | Nov 18, 2019 (0d) |
| Nov 30, 2018 | BCRX | ↓ Sell | 44,290 | $9.07 | $402K | Direct | Dec 4, 2018 (4d) |
| Sep 14, 2016 | BCRX | ↓ Sell | 8,357 | $4.27 | $36K | Direct | Sep 16, 2016 (2d) |
| Jun 19, 2015 | BCRX | ↓ Sell | 3,000 | $15.00 | $45K | Direct | Jun 22, 2015 (3d) |
| Mar 4, 2014 | BCRX | ↓ Sell | 40,734 | $12.63 | $514K | Direct | Mar 7, 2014 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BCRX insiders
Open-market trades in the last 12 months
About Alane P Barnes's insider trades
Alane P Barnes is Chief Legal Officer at Biocryst Pharmaceuticals (BCRX). Since Mar 4, 2014, Alane has reported 2 open-market purchases worth $57K and 13 sales worth $5.9M on SEC Form 4. In the last 12 months: 5 sales ($3.5M).
5 sales (58% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include shares withheld for taxes (21 filings), grants and awards (21 filings), option exercises (12 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BCRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.